Managing Nonadvanced Systemic Mastocytosis
The Expert Roundtable Session
Tyrosine kinase inhibitors in non-advanced systemic mastocytosis.
Akin C. Immunol Allergy Clin N Am. 2023;43:743–750.
Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology.
Giannetti MP, Akin C, Hufdhi R, et al. J Allergy Clin Immunol. 2021;147(4):1497-1501.e1.
Avapritinib versus placebo in indolent systemic mastocytosis.
Gotlib J, Castells M, Elberink HO, et al. NEJM. 2023;2(6):EVIDoa2200339.
Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: results of the TouchStone SM patient survey.
Mesa RA, Sullivan EM, Dubinski D, et al. Cancer. 2022;128(20):3691-3699.
Systemic mastocytosis: molecular landscape and implications for treatment.
Monaldi C, De Santis S, Mancini M, et al. Mediterr J Hematol Infect Dis. 2021;13(1):e2021046.
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
Pardanani A. Am J Hematol. 2023;98:1097-1116.
Mast cells, mastocytosis, and related disorders.
Theoharides TC, Valent P, Akin C. N Engl J Med. 2015;373(2):163-172.
Personalized management strategies in mast cell disorders: ECNM-AIM user's guide for daily clinical practice.
Valent P, Hartmann K, Schwaab J, et al. J Allergy Clin Immunol. 2022;10(8):1999-2012.e1996.
Systemic mastocytosis: multidisciplinary approach.
Zanotti R, Tanasi I, Crosera L, et al. Mediterr J Hematol Infect Dis. 2021;13(1):e2021068.
Patient Videos
Indolent Systemic Mastocytosis (ISM): The Patient Experience
Listen to these patients share their stories about being diagnosed and living with indolent SM.
Barbara, Laura, Mary Jane
Clinical Guidelines
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Arber DA, Orazi A, Hasserjian R, et al. Blood. 2016;127(20):2391-2405.
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms.
Khoury JD, Solary E, Abla O, et al. Leukemia. 2022;36(7):1703-1719.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Arber DA, Orazi A, Hasserjian RP, et al. Blood. 2022;140(11):1200-1228.
NCCN Clinical Practice Guidelines in Oncology: Systemic Mastocytosis.
National Comprehensive Cancer Network.
Total Rise in Peripheral Tryptase After Systemic Event (TRIPTASE) Calculator
National Institute of Allergy and Infectious Diseases.
Patient Resources
The Mast Cell Disease Society, Inc. (TMS)
TMS is dedicated to providing multifaceted support to patients, families, and medical professionals in the community and to leading the advancement of knowledge and research in mast cell diseases through education, advocacy, and collaboration.
The European Competence Network on Mastocytosis (ECNM)
The goal of the ECNM is to improve disease-recognition, diagnosis, and therapy in patients with mastocytosis in Europe.
Genetic and Rare Diseases Information Center
GARD helps patients find information, services, experts, financial aid, and support groups.
National Organization for Rare Disorders (NORD)
NORD is a patient advocacy organization committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.
NCCN Guidelines for Patients: Systemic Mastocytosis.
National Comprehensive Cancer Network.
Managing Nonadvanced Systemic Mastocytosis
An Expert Roundtable Session
| Faculty: | John M. Fahrenholz, MD; Lauren M. Madigan, MD; Anton Rets, MD |
| Release: | 10/26/2024 |
| Expiration: | 11/23/2024 |
